Icagen, Inc. Announces Planned Retirement Of Heyward Hull, Pharm.D., Senior Vice President, Clinical Development And Regulatory Affairs
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--March 3, 2006--Icagen, Inc. (NASDAQ: ICGN) today announced that Heyward Hull, Pharm.D., will enter into a planned retirement from his position as Senior Vice President, Clinical Development and Regulatory Affairs, effective May 17, 2006, concurrent with his reaching the customary retirement age of 65. The Company is currently conducting a search for his successor. After his retirement as SVP, Dr. Hull will continue part-time employment with Icagen as its Principal Clinical Research Scientist, a new position created by the Company.